SCHEMBL2026440

SCHEMBL2026440

O=C1c2ccc(Br)cc2CN1CCc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.44
ALDH1A1 P00352 2/20 0.42
ALDH2 P05091 1/20 0.42
ALDH3A1 P30838 1/20 0.42
KDM4E B2RXH2 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
SDCBP O00560 1/20 0.39
SDC2 P34741 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
FFAR1 O14842 1/20 0.38
ITGB3 P05106 2/20 0.38
ADAM17 P78536 1/20 0.38
ITGA2B P08514 1/20 0.38
ITGAV P06756 1/20 0.38
PTGES O14684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2023370 0.91 ALDH1A1 (0.44) DAOALDH1A1ALDH2ALDH3A1KDM4E
SCHEMBL582129 0.89 ALDH1A1 (0.51) ALDH1A1ALDH2ALDH3A1KDM4EALOX15
SCHEMBL2025564 0.88 MEN1 (0.44) ALDH1A1ALDH2ALDH3A1SDCBPSDC2
SCHEMBL5244997 0.85 KDM4E (0.55) DAOALDH1A1KDM4EALOX15TSHR
SCHEMBL17511517 0.82 PARP1 (0.49) ALDH1A1ALDH2ALDH3A1KDM4EALOX15
SCHEMBL2027141 0.81 EGFR (0.45) DAO
SCHEMBL582220 0.77 GRM5 (0.51) ALDH1A1ALDH2ALDH3A1PRMT5WDR77
SCHEMBL1500111 0.76 HDAC1 (0.49) ALDH1A1ALDH2ALDH3A1KDM4EALOX15
SCHEMBL2026621 0.75 EGFR (0.45) DAO
SCHEMBL31409495 0.74 PARP1 (0.50) ALDH1A1KDM4EALOX15TSHRSIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 US disclosed
EP-1778634-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2007-05-02 EP disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 DAO 2081/4885ALDH1A1 1582/4885ALDH2 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.